Clinical Trials Logo

Primary Immune Deficiency Diseases clinical trials

View clinical trials related to Primary Immune Deficiency Diseases.

Filter by:
  • None
  • Page 1

NCT ID: NCT03238079 Active, not recruiting - Clinical trials for Primary Immune Deficiency Diseases (PIDD)

Study of PlasmaCap IG in Adults and Children With PIDD

Start date: September 5, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy, safety, tolerability, and pharmacokinetic profile of the investigational medicinal product (IMP) and to determine, on the basis of historical control data, how it compares with other 10% intravenous immunoglobulin (IGIV) products currently licensed in North America for the treatment of subjects with primary immune deficiency diseases (PIDD).

NCT ID: NCT01617122 Recruiting - Clinical trials for Primary Immune Deficiency Diseases

Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)

Bacteriophage
Start date: October 1995
Phase: N/A
Study type: Interventional

This protocol is designed to ascertain whether the bacteriophage 0X174 neoantigen is safe and effective as an antigen used in the evaluation of primary and secondary immune responses. Bacteriophage 0X174 is given intravenously 2 billion PFU/Kg of body weight; small blood specimens of 3-5 ml (about 1 teaspoon) are collected after 15 minutes, 7 days, 14 days, and 28 days. Blood is collected at intervals following the administration of the bacteriophage and the number of phage/ml is determined by the agar overlay method using suspension of E. coli C and serially diluted patient's serum. Phage-specific IgG and IgM are measured by neutralization assay. Capacity of switch from IgM to IgG is determined.

NCT ID: NCT00634569 Completed - Clinical trials for Primary Immune Deficiency Disease

Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects

Start date: May 2008
Phase: Phase 4
Study type: Interventional

This is a multi-center, open-label study to assess the efficacy and safety of Flebogamma 5% DIF in the pediatric population.